A detailed history of Voya Investment Management LLC transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Voya Investment Management LLC holds 59,273 shares of KROS stock, worth $2.71 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
59,273
Previous 33,635 76.22%
Holding current value
$2.71 Million
Previous $1.34 Million 193.42%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$41.26 - $70.48 $1.06 Million - $1.81 Million
25,638 Added 76.22%
59,273 $3.92 Million
Q4 2023

Feb 14, 2024

SELL
$27.12 - $41.05 $1.04 Million - $1.58 Million
-38,511 Reduced 53.38%
33,635 $1.34 Million
Q3 2023

Nov 14, 2023

BUY
$31.57 - $43.02 $4,861 - $6,625
154 Added 0.21%
72,146 $2.3 Million
Q2 2023

Aug 14, 2023

BUY
$37.26 - $51.01 $67,366 - $92,226
1,808 Added 2.58%
71,992 $2.89 Million
Q4 2022

Feb 14, 2023

SELL
$39.45 - $51.77 $679,565 - $891,790
-17,226 Reduced 19.71%
70,184 $3.37 Million
Q3 2022

Mar 03, 2023

BUY
$27.8 - $40.12 $478,882 - $691,107
17,226 Added 24.54%
87,410 $3.29 Million
Q3 2022

Nov 14, 2022

BUY
$27.8 - $40.12 $2.43 Million - $3.51 Million
87,410 New
87,410 $3.29 Million
Q2 2022

Aug 15, 2022

SELL
$26.03 - $67.04 $159,589 - $411,022
-6,131 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$36.95 - $62.89 $923 - $1,572
25 Added 0.41%
6,131 $359,000
Q2 2021

Aug 16, 2021

BUY
$42.4 - $70.11 $5,172 - $8,553
122 Added 2.04%
6,106 $259,000
Q1 2021

May 17, 2021

BUY
$54.0 - $75.28 $27,216 - $37,941
504 Added 9.2%
5,984 $368,000
Q4 2020

Feb 16, 2021

BUY
$36.0 - $82.74 $197,280 - $453,415
5,480 New
5,480 $387,000

Others Institutions Holding KROS

About Keros Therapeutics, Inc.


  • Ticker KROS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,757,000
  • Market Cap $1.18B
  • Description
  • Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...
More about KROS
Track This Portfolio

Track Voya Investment Management LLC Portfolio

Follow Voya Investment Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Voya Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Voya Investment Management LLC with notifications on news.